Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib and Venetoclax in Previously Treated CLL/SLL
NCT05168930Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2022
- Primary completion
- Oct 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label trial of zanubrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (3 cohorts), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Rate of Undetectable Minimal Residual Disease at 60 weeks. Started Feb 2022; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05168930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05168930.